Results 61 to 70 of about 5,882 (203)
Bortezomib‐based chemotherapy achieved an 88.9% remission rate in Chinese pediatric patients with relapsed/refractory B‐cell acute lymphoblastic leukemia, enabling 62.5% of responders to bridge to transplantation, while T‐cell acute lymphoblastic leukemia showed no response.
Xingyu Zhao +5 more
wiley +1 more source
Non-covalent immunoproteasome inhibitors: virtual screening and in vitro test on β1i /β5i subunits
Immunoproteasome inhibition is a challenging strategy for the treatment of hematological malignancies, autoimmune and inflammatory diseases [1,2]. The search for non-covalent inhibitors of the immunoproteasome β1i/β5i catalytic subunits could be a new ...
Marco Tutone +6 more
core
This study underscores the critical role of PTMs in mediating cellular responses to X‐ray and Carbon ion irradiation radiotherapy in HNSCC. The integration of multi‐omics data provides insights into the molecular mechanisms underlying radiation‐induced changes, offering valuable clues for improving therapeutic outcomes and advancing precision medicine ...
Fan‐Tong Xia +13 more
wiley +1 more source
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia
Pharmacologic targeting of chromatin-associated protein complexes has shown significant responses in KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) but resistance frequently develops to single agents.
Nuria Tubío-Santamaría +25 more
doaj +1 more source
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
Immunoproteasome acted as immunotherapy ‘coffee companion’ in advanced carcinoma therapy
Immunoproteasome is a specialized form of proteasome which plays a crucial role in antigen processing and presentation, and enhances immune responses against malignant cells.
Shaoyan Shi +4 more
doaj +1 more source
Abstract Understanding the turnover of proteins in tissues gives information as to how external stimuli result in phenotypic change. Nowhere is such phenotypic change more conspicuous than skeletal muscle, which can be effectively remodelled by increased loading, ageing and unloading (disuse), all of which are subject to modification by nutrition and ...
Changhyun Lim +12 more
wiley +1 more source
Proteasome inhibitors (PIs) are approved backbone treatments in multiple myeloma. More recently, inhibition of proteasome activity with the PI bortezomib has been clinically evaluated as a novel treatment strategy in pediatric acute lymphoblastic ...
Lenka Besse +7 more
doaj +1 more source
Neuronal Induction of the Immunoproteasome in Huntington's Disease [PDF]
Huntington's disease (HD) inclusions are stained with anti-ubiquitin and anti-proteasome antibodies. This, together with proteasome activity studies on transfected cells, suggest that an impairment of the ubiquitin-proteasome system (UPS) may be key in HD pathogenesis.
Díaz-Hernández, Miguel +8 more
openaire +4 more sources
Living donor heart valves offer superior durability for pediatric patients but trigger immune rejection. Lentiviral delivery of viral immune‐evasion genes US2 and Serpin b9 into donor valve cells and valve tissue suppresses HLA expression, reduces PBMC clustering and cytotoxic killing, and induces transcriptional immune‐tolerance programs, paving the ...
Abraham van Wijk +11 more
wiley +1 more source

